To expedite drug development for rare pediatric diseases, the FDA released a draft guidance on a collaborative approach using Gaucher disease as a model. The guidance describes the new approach, developed in partnership with the EMA, for companies to collaborate and test multiple drug products in the same clinical trials, reducing the number of patients needed in a placebo control arm.